A review on various aspects of quality by design [qbd] on new drug approval

Sireesha Badri; Kusuma B; Priyanka N; Prathyusha B; Malisha Sd

doi:10.37022/jpmhs.v7i4.119

Authors

Badri. Sireesha Associate professor, Dr.Samuel George Institute Of Pharmaceutical Sciences, TarlupaduRoad , Markapur,Prakasam Dt, Pincode-523316
B. Kusuma B.Pharmacy,Dr.Samuel George Institute Of Pharmaceutical Sciences, Tarlupadu Road , Markapur,Prakasam Dt, Pincode-523316
N. Priyanka B.Pharmacy,Dr.Samuel George Institute Of Pharmaceutical Sciences, Tarlupadu Road , Markapur,Prakasam Dt, Pincode-523316
B. Prathyusha B.Pharmacy,Dr.Samuel George Institute Of Pharmaceutical Sciences, Tarlupadu Road , Markapur,Prakasam Dt, Pincode-523316
Sd. Malisha B.Pharmacy,Dr.Samuel George Institute Of Pharmaceutical Sciences, Tarlupadu Road , Markapur,Prakasam Dt, Pincode-523316

DOI:

https://doi.org/10.37022/jpmhs.v7i4.119

Keywords:

Quality by design, Product Profile, Process analytical technology

Abstract

Microneedles and microfluidics are technologies that can be combined to create devices for biomedical applications such as drug delivery, wound healing, biosensing, body fluid sampling, and health monitoring. In vitro microfluidic drug delivery is closely linked to the emerging concept of lab-on-a-chip systems for cell culture studies. These systems can be used to administer drugs at the cellular or tissue level, assess the therapeutic index, and potentially be applied in personalized medicine

Downloads

Download data is not yet available.

References

Huang J, Kaul G, Cai C, Chatlapalli R, Hernandez-abad P, Ghosh K, et al. Quality by design case study : An integrated multivariate approach to drug product and process development. 2009;382:23–32.

Food and Drug Administration. Final Report on Pharmaceutical cGMPs for the 21st Century - A Risk Based Approach. http://www.fda.gov/ cder/ gmp/ gmp 2004/ GMP_ final report 2004.htm. 2016.

A review on quality by design, Sachin L. Darkunde, January- March,2018;5(1):1-6, International Journal of Pharmaceutical Chemistry and Analysis

International Society for Pharmaceutical Engineering (ISPE) (2011) Part 1 - Product Realization using Quality by Design (QbD): Concepts and Principles. In: ISPE Guide Series: Product Quality Lifecycle Implementation (PQLI®) from Concept to Continual Improvement.

Quality by Design-A Review, Manohar D. Kengar*, Jameer A. Tamboli, Chandrakant S, vol7 Issue04, PharmaTutor ( pharmacy Infopedia)

Purohit PJ and Shah KV. Quality By Design (Qbd): New Parameter For Quality Improvement & Pharmaceutical Drug Development,Pharma Science Monitor. Int J Pharm Sci. 2013;

Fahmy R., Kona R., Dandu R. Quality by design I: application of failure mode effect analysis (FMEA) and Plackett–Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech. 2012;13(4):1243–1254. doi: 10.1208/s12249-012-9844-x

Ana Simoes, Francisco Veiga, Carla Vitorino and Ana Figueiras: A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach. Journal of Pharmaceutical Sciences xxx 2018; 1-10.

SAS Institute, Inc. (2019) JMP® 15 Design of experiments guide. SAS Institute Inc., Cary, NC.

Review Article: Quality by Design (QbD), Mimansha patel, vol8Issue11,2018, Indoamerican Journal of Pharmaceutical Research.

ICH Harmonised Tripartite Guideline Pharmaceutical Development Q8 (R2) current step 4 version dated 2009 AUGUST

Pharmaceutical Quality for the 21st Century: A Risk-Based Approach .

Leuenberger H, Puchkov M, Krausbauer E, Betz G, Manufacturing pharmaceutical granules, Is the granulation end-point a myth, Powder Technology, 189, 2009, 141–148. :

Vince, M., 2011. Quality by Design, in Process Understanding: For Scale-Up and Manufacture of Active Ingredients ed I. Houson, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim,Germany.

H.A. Wagdy, R.S. Hanafi, R.M. El-Nashar, H.Y. Aboul-EneinJ.Sep. Sci., 36 (2013),p. 170.F. Szabolcs, F. Jeno˝, M. Imre, G. KatalinJ. Chromatogr. A., 1216 (2009), pp. 7816-7823

U. S. Food and Drug Administration. Guidance for Industry: Q8, Q9, and Q10 questions and answers. 2011..

Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26–34. doi: 10.1038/nbt0109-26. [DOI] [PubMed] [Google Scholar]

ICH Quality Implementation Working Group. Points to consider. ICH-endorsed guide for ICH Q8/Q9/Q10 implementation. 2011.

Bhattacharya J. Quality Risk Management –Understanding and Control the Risk in Pharmaceutical Manufacturing Industry. International Journal of Pharmaceutical Science Invention 2015; 4: 29-41.

Jain S. Quality by design (QbD): a comprehensive understanding of implementation and challenges in pharmaceuticals development. Int J Pharm Pharm Sci. 2013; 6: 29-35.

Glodek, M. Liebowitz, S. McCarthy, R. McNally, G. Oksanen, C. Schultz, T. et al. Pharm. Eng., 26: 1-11 (2006) .

Ian House Process Understanding: for Scale-up and Manufacturing method of Activeingrendients in the pharmaceutical industry .

Remy B, Glasser BJ, Khinast JG, The effect of mixer properties and fill level on granular flow in a bladed mixer. AIChE Journal, 56, 2010, 336–353.

Gawade, A. Chemate, S. Kuchekar, A. Pharmaceutical Quality by Design: A New Approach in pharmaceutical approach ..

Nasr M. Risk-based CMC review paradigm, Advisory committee for pharmaceutical science meeting, 2004. 13. Food and Drug Administration CDER. Guidance for indust